Aluminum phosphate, Bone Phosphate, Calcium phosphate, Calcium Orthophosphate, Calcium Phosphate Dibasic Anhydrous, Calcium Phosphate-Bone Ash, Calcium Phosphate Dibasic Dihydrate, Calcium Phosphate Dibasique Anhydre, Calcium Phosphate Dibasique Dihydrate, Calcium Phosphate Tribasic, Calcium Phosphate Tribasique, Dibasic Calcium Phosphate Dihydrate, Di-Calcium Phosphate, Dicalcium Phosphate, Dicalcium Phosphates, Neutral Calcium Phosphate, Orthophosphate de Calcium, Phosphate d'Aluminium, Phosphate de Calcium, Phosphate de Magnésium, Phosphate Neutre de Calcium, Phosphate d'Os, Phosphate Tricalcium, Precipitated Calcium Phosphate, Précipitation du Phosphate de Calcium, Précipité de Phosphate de Calcium, Tertiary Calcium Phosphate, Tricalcium Phosphate, Whitlockite, Magnesium Phosphate, Merisier, Potassium phosphate, Dibasic Potassium Phosphate, Dipotassium Hydrogen Orthophosphate, Dipotassium Monophosphate, Dipotassium Phosphate, Monobasic Potassium Phosphate, Potassium Acid Phosphate, Potassium Biphosphate, Potassium Dihydrogen Orthophosphate, Potassium Hydrogen Phosphate, Phosphate de Dipotassium, Phosphate d'Hydrogène de Potassium, Phosphate de Potassium, Phosphate de Potassium Dibasique, Phosphate de Potassium Monobasique, Sodium phosphate, Anhydrous Sodium Phosphate, Dibasic Sodium Phosphate, Disodium Hydrogen Orthophosphate, Disodium Hydrogen Orthophosphate Dodecahydrate, Disodium Hydrogen Phosphate, Disodium Phosphate, Phosphate of Soda, Sales de Fosfato, Sels de Phosphate, Sodium Orthophosphate, Orthophosphate Disodique d'Hydrogène, Phosphate Disodique d'Hydrogène, Orthophosphate de Sodium, Phosphate de Sodium Anhydre, Phosphate de Sodium Dibasique, Phosphorus.
Phosphate salts refers to many different combinations of the chemical phosphate with salts and minerals. Foods high in phosphate include dairy products, whole grain cereals, nuts, and certain meats. Phosphates found in dairy products and meats seem to be more easily absorbed by the body than phosphates found in cereal grains. Cola drinks contain a lot of phosphate - so much, in fact, that they can cause too much phosphate in the blood.
People use phosphate salts for medicine. Be careful not to confuse phosphate salts with substances such as organophosphates, or with tribasic sodium phosphates and tribasic potassium phosphates, which are very poisonous.
Phosphate salts are taken by mouth for treating blood phosphate levels that are too low and blood calcium levels that are too high, and for preventing kidney stones. They are also taken for treating osteomalacia (often called “rickets” in children), a condition caused by a mineral imbalance in the body that leads to softening of the bones. Phosphate salts are also used for improving exercise performance, as an antacid for gastroesophageal reflux disease (GERD), and as a laxative for emptying the bowels before surgery.
Phosphate salts and calcium are applied to sensitive teeth to reduce pain.
Rectally, phosphate salts are used as a laxative to clean the bowels before surgery or intestinal tests.
Healthcare providers sometimes give potassium phosphate intravenously (by IV) for treating low phosphate and high calcium levels in the blood, and for preventing low phosphate in patients who are being tube-fed.
How does it work?
Phosphates are normally absorbed from food and are important chemicals in the body. They are involved in cell structure, energy transport and storage, vitamin function, and numerous other processes essential to health. Phosphate salts can act as laxatives by causing more fluid to be drawn into the intestines and stimulating the gut to push out its contents faster.
- Preparing the bowel for a medical procedure. Sodium phosphate tablets (OsmoPrep, Visicol, Salix Pharmaceuticals, Raleigh, NC) are FDA-approved for cleansing the colon before a colonoscopy. Over-the-counter sodium phosphate solutions and enemas may also be used for bowel cleansing before medical procedures.
- Low phosphate levels in the blood. Taking sodium or potassium phosphate by mouth is effective for preventing or treating low phosphate levels in the blood. Intravenous phosphate salts may also treat low phosphate levels in the blood when used under the supervision of a physician.
Likely Effective for...
- Constipation. Sodium phosphate is an FDA-permitted over-the-counter (OTC) ingredient for the treatment of constipation. These products are taken by mouth or used as enemas.
- Indigestion. Aluminum phosphate and calcium phosphate are FDA-permitted ingredients used in antacids.
- High calcium levels in the blood. Taking phosphate salt (except calcium phosphate) by mouth is likely effective for treating high levels of calcium in the blood. But intravenous phosphate salts should not be used.
Possibly Effective for...
- Kidney stones (nephrolithiasis). Taking potassium phosphate by mouth might help prevent calcium kidney stones from forming in patients with high urine levels of calcium.
Possibly Ineffective for...
- Athletic performance. Some early research suggests that taking sodium phosphate by mouth four times daily for 6 days might increase athletic performance in male cyclists. However, most evidence shows that taking phosphate salts by mouth does not improve exercise performance.
Insufficient Evidence to Rate Effectiveness for...
- Diabetes complication (diabetic ketoacidosis). Early research suggests that taking potassium phosphate intravenously (by IV) does not improve a diabetes complication in which the body produces too many blood acids called ketones. People with this condition should only be given phosphates if they have low phosphate levels.
- Complications that occur upon eating in people who were previously starving (refeeding syndrome). Limited research shows that giving sodium and potassium phosphates intravenously (by IV) over 24 hours prevents refeeding syndrome when restarting nutrition in people who are severely malnourished or starved.
- Sensitive teeth.
- Other conditions.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Phosphate salts containing sodium, potassium, aluminum, or calcium are LIKELY SAFE for most people when taken by mouth short-term, when sodium phosphate is inserted into the rectum appropriately and short-term, or when potassium phosphate is used intravenously (by IV) under the supervision of a physician.
Phosphate (expressed as phosphorus) is POSSIBLY UNSAFE when taken in amounts higher than 4 grams per day for adults younger than 70 years of age and 3 grams per day for people who are older.
Regular long-term use can upset the balance of phosphates and other chemicals in the body and should be monitored by a healthcare professional to avoid serious side effects. Phosphate salts can irritate the digestive tract and cause stomach upset, diarrhea, constipation, and other problems.
Do not confuse phosphate salts with substances such as organophosphates, or with tribasic sodium phosphates and tribasic potassium phosphates, which are very poisonous.
IMAGESBrowse through our medical image collection to see and discover unique diseases and conditions See Images
Children: Phosphate salts are LIKELY SAFE for children when used at the recommended daily allowances of 460 mg for children 1-3 years of age; 500 mg for children 4-8 years of age; and 1250 mg for children 9-18 years of age. Phosphate salts are POSSIBLY UNSAFE if the amount of phosphate consumed (expressed as phosphorous) exceeds the tolerable upper intake level (UL). The ULs are 3 grams per day for children 1-8 years; and 4 grams per day for children 9 years and older.
Heart disease: Avoid using phosphate salts that contain sodium if you have heart disease.
Fluid retention (edema): Avoid using phosphate salts that contain sodium if you have cirrhosis, heart failure, or other conditions that can cause edema.
High levels of calcium in the blood (hypercalcemia): Use phosphate salts cautiously if you have hypercalcemia. Too much phosphate could cause calcium to be deposited where it shouldn't be in your body.
High levels of phosphate in the blood: People with Addison's disease, severe heart and lung disease, kidney disease, thyroid problems, or liver disease are more likely than other people to develop too much phosphate in their blood when they take phosphate salts. Use phosphate salts only with the advice and ongoing care of a healthcare professional if you have one of these conditions.
Kidney disease: Use phosphate salts only with the advice and ongoing care of a healthcare professional if you have kidney problems.
BisphosphonatesInteraction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Bisphosphonate medications and phosphate salts can both lower calcium levels in the body. Taking large amounts of phosphate salts along with bisphosphonate medications might cause calcium levels to become too low.
Some bisphosphonates include alendronate (Fosamax), etidronate (Didronel), risedronate (Actonel), tiludronate (Skelid), and others.
The following doses have been studied in scientific research:
- For raising phosphate levels that are too low or lowering calcium levels that are too high: Healthcare providers measure the levels of phosphate and calcium in the blood and give just enough phosphate to correct the problem.
The adequate intakes (AI) for infants are: 100 mg for infants 0-6 months old and 275 mg for infants 7-12 months of age.
Tolerable Upper Intake Levels (UL), the highest intake level at which no unwanted side effects are expected, for phosphate (expressed as phosphorus) per day are: children 1-8 years, 3 grams per day; children and adults 9-70 years, 4 grams; adults older than 70 years, 3 grams; pregnant women 14-50 years, 3.5 grams; and breast-feeding women 14-50 years, 4 grams.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors
Health Solutions From Our Sponsors
Alvarez-Arroyo MV, Traba ML, Rapado TA, et al. Correlation between 1.25 dihydroxyvitamin D serum levels and fractional rate of intestinal calcium absorption in hypercalciuric nephrolithiasis. Role of phosphate. Urol Res 1992;20:96-7. View abstract.
Becker GL. The case against mineral oil. Am J Digestive Dis 1952;19:344-8. View abstract.
Bredle DL, Stager JM, Brechue WF, Farber MO. Phosphate supplementation, cardiovascular function, and exercise performance in humans. J Appl Physiol 1988;65:1821-6. View abstract.
Bugg, NC and Jones, JA. Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit. Anaesthesia 1998;53(9):895-902. View abstract.
Campisi P, Badhwar V, Morin S, Trudel JL. Postoperative hypocalcemic tetany caused by Fleet Phospho-Soda preparation in a patient taking alendronate sodium. Dis Colon Rectum 1999;42:1499-501. View abstract.
Carey CF, Lee HH, Woeltje KF (eds). Washington Manual of Medical Therapeutics. 29th ed. New York, NY: Lippincott-Raven, 1998.
Clarkston WK, Tsen TN, Dies DF, et al. Oral sodium phosphate versus sulfate-free polyethylene glycol electrolyte lavage solution in outpatient preparation for colonoscopy: a prospective comparison. Gastrointest Endosc 1996;43:42-8. View abstract.
DiPalma JA, Buckley SE, Warner BA, et al. Biochemical effects of oral sodium phosphate. Dig Dis Sci 1996;41:749-53. View abstract.
Duffy DJ, Conlee RK. Effects of phosphate loading on leg power and high intensity treadmill exercise. Med Sci Sports Exerc 1986;18:674-7. View abstract.
Elliott, GT and McKenzie, MW. Treatment of hypercalcemia. Drug Intell Clin Pharm 1983;17(1):12-22. View abstract.
Fauci AS, Braunwald E, Isselbacher KJ, et al. Harrison's Principles of Internal Medicine, 14th ed. New York, NY: McGraw-Hill, 1998.
FDA OTC ingredients list, April 2010. Available at: www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135691.pdf (accessed 2/7/15).
Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997;29:103-5. View abstract.
Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 1998;280:1067-73. View abstract.
Fisher, JN and Kitabchi, AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 1983;57(1):177-80. View abstract.
Folland, JP, Stern, R, and Brickley, G. Sodium phosphate loading improves laboratory cycling time-trial performance in trained cyclists. J Sci Med Sport 2008;11(5):464-8. View abstract.
Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press, 1999. Available at: http://books.nap.edu/books/0309063507/html/index.html.
Galloway SD, Tremblay MS, Sexsmith JR, Roberts CJ. The effects of acute phosphate supplementation in subjects of different aerobic fitness levels. Eur J Appl Physiol Occup Physiol 1996;72:224-30. View abstract.
Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
Harmelin DL, Martin FR, Wark JD. Antacid-induced phosphate depletion syndrome presenting as nephrolithiasis. Aust NZ J Med 1990;20:803-5. View abstract.
Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr 2002;21:239-44.. View abstract.
Heaton KW, Lever JV, Barnard RE. Osteomalacia associated with cholestyramine therapy for post-ileectomy diarrhea. Gastroenterology 1972;62:642-6. View abstract.
Helikson MA, Parham WA, Tobias JD. Hypocalcemia and hyperphosphatemia after phosphate enema use in a child. J Pediatr Surg 1997;32:1244-6. View abstract.
Heller HJ, Reza-Albarran AA, Breslau NA, Pak CY. Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria. J Urol 1998;159:1451-5; discussion 1455-6. View abstract.
Hergesell O, Ritz E. Phosphate binders on iron basis: a new perspective? Kidney Intl Suppl 1999;73:S42-5. View abstract.
Hill AG, Teo W, Still A, et al. Cellular potassium depletion predisposes to hypokalaemia after oral sodium phosphate. Aust N Z J Surg 1998;68:856-8. View abstract.
Hu, S, Shearer, GC, Steffes, MW, Harris, WS, and Bostom, AG. Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia. Am J Kidney Dis 2011;57(1):181-2. View abstract.
Insogna KL, Bordley DR, Caro JF, Lockwood DH. Osteomalacia and weakness from excessive antacid ingestion. JAMA 1980;244:2544-6. View abstract.
Leung AC, Henderson IS, Halls DJ, Dobbie JW. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed) 1983;286:1379-81. View abstract.
Lindsay R, Nieves J, Formica C, et al. Randomized controlled study of the effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5. View abstract.
Lindsay R, Nieves J, Henneman E, et al. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993;77:1535-9. View abstract.
Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf 2003;26:1093-115. View abstract.
Monsen ER, Cook JD. Food iron absorption in human subjects IV. The effects of calcium and phosphate salts on the absorption of nonheme iron. Am J Clin Nutr 1976;29:1142-8. View abstract.
OsmoPrep Prescribing information. Salix Pharmaceuticals, Raleigh, NC. October 2012. (http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021892s006lbl.pdf, accessed 02/24/15).
Perreault MM, Ostrop NJ, Tierney MG. Efficacy and safety of intravenous phosphate replacement in critically ill patients. Ann Pharmacother 1997;31:683-8. View abstract.
Peters T, Apt L, Ross JF. Effect of phosphates upon iron absorption studied in normal human subjects and in an experimental model using dialysis. Gastroenterology 1971;61:315-22. View abstract.
Roberts DH, Knox FG. Renal phosphate handling and calcium nephrolithiasis: role of dietary phosphate and phosphate leak. Semin Nephrol 1990;10:24-30. View abstract.
Rosen GH, Boullata JI, O'Rangers EA, et al. Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia. Crit Care Med 1995;23:1204-10. View abstract.
Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis 1989;13:194-9. View abstract.
Saadeh G, Bauer T, Licata A, Sheeler L. Antacid-induced osteomalacia. Cleve Clin J Med 1987;54:214-6. View abstract.
Savica, V, Calo, LA, Monardo, P, et al. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia. J Ren Nutr 2009;19(1):69-72. View abstract.
Schaiff, RA, Hall, TG, and Bar, RS. Medical treatment of hypercalcemia. Clin Pharm 1989;8(2):108-21. View abstract.
Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. New Engl J Med 1989;320:1110-3. View abstract.
Schwarz KB, Goldstein PD, Witztum JL, et al. Fat-soluble vitamin concentrations in hypercholestrolemic children treated with colestipol. Pediatrics 1980;65:243-50. View abstract.
Shils ME, Olson JA, Shike M, Ross AC, eds. Modern Nutrition in Health and Disease. 9th ed. Baltimore, MD: Williams & Wilkins, 1999.
Spencer H, Menaham L. Adverse effects of aluminum-containing antacids on mineral metabolism. Gastroenterology 1979;76:603-6. View abstract.
Terlevich A, Hearing SD, Woltersdorf WW, et al. Refeeding syndrome: effective and safe treatment with Phosphates Polyfusor. Aliment Pharmacol Ther 2003;17(10):1325-9. View abstract.
West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975;16:93-8. View abstract.
Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone (1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003;88:4214-20. View abstract.
Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 1996;276:631-6. View abstract.
Yates AA, Schlicker SA, Suitor CW. Dietary reference intakes: The new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699-706. View abstract.
Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.